APA (7th ed.) Citation

F, Z., L, L., J, L., B, X., W, Z., Q, H., . . . H, Z. (2019). Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nature communications, 10(1), 4109. https://doi.org/10.1038/s41467-019-11893-4

Chicago Style (17th ed.) Citation

F, Zou, et al. "Engineered Triple Inhibitory Receptor Resistance Improves Anti-tumor CAR-T Cell Performance via CD56." Nature Communications 10, no. 1 (2019): 4109. https://doi.org/10.1038/s41467-019-11893-4.

MLA (9th ed.) Citation

F, Zou, et al. "Engineered Triple Inhibitory Receptor Resistance Improves Anti-tumor CAR-T Cell Performance via CD56." Nature Communications, vol. 10, no. 1, 2019, p. 4109, https://doi.org/10.1038/s41467-019-11893-4.